Ketogen Inc.

Ketogen Inc.

Ketogen is a biotechnology company developing a new class of small molecule therapeutics for the treatment of epilepsy. Our approach brings to the brain several anti-seizure mechanisms from both medication and diet therapies to provide patients with difficulty to control seizures with a dual-action oral pill with enhanced efficacy and safety. These multivalent proprietary ketogenic anti-epileptic drugs (AEDs) have composition of matter and full patent life protection, and offer risk mitigation, unique pharmacological properties, novel mechanism of action (MOA), ease of use, greater effectiveness while minimizing dose- and drug- related side effects. Our current product pipeline includes new chemical entities targeting partial onset seizures and rare childhood epilepsies. Ketogen has a team with strong, relevant drug development/pharma experience that is able to attain fast to patients as well as fast to market.

Area of focus: 
Neuroscience
Commencement date: 
06/01/2016

Share